The Analyst Verdict: IGM Biosciences In The Eyes Of 5 Experts
Portfolio Pulse from Benzinga Insights
IGM Biosciences (NASDAQ:IGMS) has received mixed analyst ratings over the past three months, with a recent average price target of $18.4, reflecting a 4.55% increase. Analysts have adjusted their ratings and price targets, indicating varied expectations for the company's performance. Despite a positive revenue growth trend, IGM Biosciences faces challenges with profitability and asset utilization.
September 05, 2024 | 2:00 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
IGM Biosciences has received mixed analyst ratings, with a recent average price target of $18.4, up 4.55%. Analysts have adjusted their ratings, reflecting varied expectations. The company shows strong revenue growth but faces profitability challenges.
The mixed analyst ratings and adjustments in price targets suggest uncertainty in the short-term performance of IGMS. The increase in average price target indicates some positive sentiment, but the company's financial challenges, such as low profitability and asset utilization, may offset this. Therefore, the short-term impact on the stock price is likely neutral.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100